217645-70-0 Usage
Description
Urea, N-[5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)Methyl]-2-Methyl-1-piperazinyl]-2-oxoethoxy]phenyl]is a complex organic compound with a molecular structure that features a urea group attached to a phenyl ring with various substituents, including a chloro group, a 2-oxoethoxy group, and a 2-methyl-1-piperazinyl group with a fluorophenylmethyl substituent. Urea, N-[5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)Methyl]-2-Methyl-1-piperazinyl]-2-oxoethoxy]phenyl]is likely to have specific biological activities and may be used in various applications due to its unique structure and functional groups.
Uses
Used in Pharmaceutical Industry:
Urea, N-[5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)Methyl]-2-Methyl-1-piperazinyl]-2-oxoethoxy]phenyl]is used as a chemotaxis assay agent for studying the responses of HEK293 cells expressing human C-C motif chemokine receptor 1 (CCR1) to CC motif ligand 3 (CCL3)-induced cell migration. Its application in this context is due to its ability to act as a CCR1 inhibitor, allowing researchers to assess the effects of CCR1 on cell migration and epithelial-mesenchymal transition (EMT).
Used in Autoimmune Disease Research:
In the pharmaceutical industry, Urea, N-[5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)Methyl]-2-Methyl-1-piperazinyl]-2-oxoethoxy]phenyl]is also used as a CCR1 antagonist to investigate the role of CCR1 in leukocyte trafficking and its expression in certain autoimmune diseases. The compound has demonstrated the ability to displace CCR1 ligands such as MIP-1α, RANTES, and MCP-3, with high selectivity for CCR1 over other G protein-coupled receptors.
Used in Multiple Sclerosis Treatment:
Urea, N-[5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)Methyl]-2-Methyl-1-piperazinyl]-2-oxoethoxy]phenyl]has been shown to reduce the severity of experimental allergic encephalomyelitis, a rat model of multiple sclerosis, when administered at a dosage of 50 mg/kg. This suggests its potential use in the development of treatments for multiple sclerosis.
Used in Sepsis Treatment:
The compound also has applications in the treatment of sepsis, as it has been shown to decrease the inflammatory response during the condition. This highlights its potential as an anti-inflammatory agent in the context of severe infections.
Used in Rheumatoid Arthritis Research:
Urea, N-[5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)Methyl]-2-Methyl-1-piperazinyl]-2-oxoethoxy]phenyl]is used to block the migration of monocytes isolated from rheumatoid arthritis patients, providing insights into the role of CCR1 in the disease progression and potential therapeutic targets.
Used in Lupus Nephritis Treatment:
In a mouse model of lupus nephritis, the compound has been shown to prevent macrophage and T-cell recruitment, indicating its potential use in the treatment of this autoimmune kidney disease.
Biochem/physiol Actions
BX471 blocks CCR1 and downregulates the mRNA expression of ICAM-1, P-selectin and E-selectin. It decreases the inflammatory responses in sepsis, prevents monocyte recruitment in inflammation sites in rheumatoid arthritis patients and inhibits interstitial leukocyte recruitment and fibrosis in mouse model of lupus nephritis.
in vitro
competition binding studies revealed that bx 471 was able to displace the ccr1 ligands macrophage inflammatory protein-1a, rantes, and monocyte chemotactic protein-3 with high affinity. bx 471 was a potent functional antagonist based on its ability to inhibit plenty of ccr1-mediated effects. bx 471 also demonstrated a greater than 10,000-fold selectivity for ccr1 compared with 28 g-protein-coupled receptors [1].
in vivo
pharmacokinetic studies demonstrated that bx 471 was orally active with a 60% bioavailability in dogs. furthermore, in a rat experimental allergic encephalomyelitis model of multiple sclerosis, bx 471 effectively reduces disease [1].
references
[1] liang m, mallari c, rosser m, ng hp, may k, monahan s, bauman jg, islam i, ghannam a, buckman b, shaw k, wei gp, xu w, zhao z, ho e, shen j, oanh h, subramanyam b, vergona r, taub d, dunning l, harvey s, snider rm, hesselgesser j, morrissey mm, perez hd. identification and characterization of a potent, selective, and orally active antagonist of the cc chemokine receptor-1. j biol chem. 2000 jun 23;275(25):19000-8.
Check Digit Verification of cas no
The CAS Registry Mumber 217645-70-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,7,6,4 and 5 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 217645-70:
(8*2)+(7*1)+(6*7)+(5*6)+(4*4)+(3*5)+(2*7)+(1*0)=140
140 % 10 = 0
So 217645-70-0 is a valid CAS Registry Number.
217645-70-0Relevant articles and documents
18F-labelling of a potent nonpeptide CCR1 antagonist: Synthesis of 1-(5-chloro-2-{2-[(2r)-4-(4-[18F]fluorobenzyl)-2-methylpiperazin- 1-yl]-2-oxoethoxy}phenyl)urea in an automated module
Maeding,Fuechtner,Johannsen,Steinbach,Hilger,Friebe,Halks-Miller,Horuk,Mohan
, p. 253 - 262 (2007/10/03)
The synthesis of 1-(5-chloro-2-{2-[(2R)-4-(4-[18F]fluorobenzyl)- 2-methylpiperazin-1-yl]-2-oxoethoxy}phenyl)urea ([18F]4), a potent nonpeptide CCR1 antagonist, is described as a module-assisted two-step one-pot procedure. The final p
Piperazine derivatives and their use as anti-inflammatory agents
-
Page 59, (2008/06/13)
This invention is directed to acyl piperazine derivatives which are useful as anti-inflammatory agents. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat inflammatory disorders in humans.
